The UK and US have agreed to a major bilateral deal that will ensure no duties on British medicine exports being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This commitment ensures that import taxes on these key exports will be held at nothing for a timeframe of 36 months.
This development comes after earlier warnings to dramatically increase import taxes on patented pharmaceutical imports, with increases discussed reaching one hundred percent.
"This deal with the United Kingdom strengthens the worldwide climate for innovative medicines and introduces much-needed equity to American-British medicine commerce," a release said.
Trade Importance
Drugs constitute one of the UK's largest exports to the United States, which is by far the primary destination for leading UK drugmakers.
Statistics show that in the year leading up to the third quarter, the UK sold drugs worth £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that timeframe.
"This agreement secures jobs, stimulates funding and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official commented.
Detailed UK Commitments
The deal entails several key pledges from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to raise overall NHS spending on treatments from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. In the past, repayments exceeded 20%.
Recent Tensions
The deal comes amid a long-running tension between the drug companies and the British authorities over medicine costs and NHS adoption.
This friction were intensified by claims that US customers were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
